2022
DOI: 10.1186/s12985-022-01921-z
|View full text |Cite
|
Sign up to set email alerts
|

IgG response to spike protein of SARS-CoV-2 in healthy individuals and potential of intravenous IgG as treatment for COVID-19

Abstract: Background The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19), which is currently a worldwide pandemic. There are limited available treatments for severe COVID-19 patients. However, some evidence suggests that intravenous immunoglobulin (IVIg) provides clinical benefits for these patients. Methods We administered IVIg to 23 severe COVID-19 patients, and all of them survived. Four rel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 35 publications
0
1
0
Order By: Relevance
“…Standard preparations of commercial IVIg contain > 98% of IgG: IgA and IgM are virtually absent whereas normal plasma contains about 72% of IgG, 17% of IgA and 10% of IgM (11). IVIg pre-pandemic commercial batches of IVIg was showed to contain cross-reactive Sars-Cov-2 receptor binding domain antibodies (12): as such, early clinical study suggested a potential benefit of IVIg for patients with severe COVID-19 (13). The spread of the disease lead to a progressive significant increase of Sars-Cov-2 antibodies in commercial IVIg batches (14-17) which may represent an alternative strategy to plasma (18) in immunocompromised patients.…”
Section: Introductionmentioning
confidence: 99%
“…Standard preparations of commercial IVIg contain > 98% of IgG: IgA and IgM are virtually absent whereas normal plasma contains about 72% of IgG, 17% of IgA and 10% of IgM (11). IVIg pre-pandemic commercial batches of IVIg was showed to contain cross-reactive Sars-Cov-2 receptor binding domain antibodies (12): as such, early clinical study suggested a potential benefit of IVIg for patients with severe COVID-19 (13). The spread of the disease lead to a progressive significant increase of Sars-Cov-2 antibodies in commercial IVIg batches (14-17) which may represent an alternative strategy to plasma (18) in immunocompromised patients.…”
Section: Introductionmentioning
confidence: 99%